A Phase II, Single Arm, Multi-center Trial to Evaluate the Efficacy and Safety of Tisagenlecleucel in Chinese Pediatric and Young Adult Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 26 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tisagenlecleucel (Primary)
Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
Focus Therapeutic Use
Sponsors Novartis Pharmaceuticals

Most Recent Events

03 Feb 2022 Planned initiation date changed from 31 Jan 2022 to 30 Nov 2021.
03 Feb 2022 Status changed from not yet recruiting to withdrawn prior to enrolment. This study was cancelled before enrolling any patients for business related reasons.
12 Jan 2022 Planned initiation date changed from 30 Nov 2021 to 31 Jan 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight